Tyra Biosciences (United States)

Homepage: tyra.bio

Alternate names: Tyra, Tyra Biosciences, Tyra Biosciences, Inc.

ROR: 008a2q193

OpenAlex ID: I4405262928

Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing

2022 · Olaf Neumann, Timothy C. Burn, et al. · British Journal of Cancer · 89

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma

2024 · L. Goyal, D. DiToro, et al. · Annals of Oncology · 52

Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia

2024 · Robert L. Hudkins, Eric Allen, et al. · Journal of Medicinal Chemistry · 37

TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia

2025 · Jacqueline H. Starrett, Clara Lemoine, et al. · JCI Insight · 7

Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity

2025 · Jacqueline H. Starrett, Eric L. Allen, et al. · Molecular Cancer Therapeutics · 3

A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301).

2025 · Aaron Richard Hansen, Alison Yan Zhang, et al. · Journal of Clinical Oncology · 3

TYRA-430: First reversible FGFR4/3 inhibitor designed to overcome current challenges in FGF19-driven hepatocellular carcinoma treatment.

2025 · Mohamed A. Ahmed, Jacqueline Starrett, et al. · Journal of Clinical Oncology · 2

TYRA-200: Potent Against FGFR2 Fusions, Molecular Brake Mutations and Gatekeeper Resistance

2022 · E. Allen, A. Balcer, et al. · European Journal of Cancer · 2

Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance Mutations

2026 · Robert L. Hudkins, Eric Allen, et al. · Journal of Medicinal Chemistry · 1

ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib (formerly TYRA-300) in the SURF301 trial.

2026 · Andrew J. Murtha, Valentina Boni, et al. · Journal of Clinical Oncology · 1

288eTiP A multicenter, open-label, first-in-human study of TYRA-430 in advanced hepatocellular carcinoma and other solid tumors with activating FGF/FGFR pathway aberrations (SURF431)

2025 · L. Goyal, R. Al-Rajabi, et al. · Annals of Oncology · 1

A multicenter, open-label, first-in-human study of TYRA-200 in advanced intrahepatic cholangiocarcinoma and other solid tumors with activating FGFR2 gene alterations (SURF201).

2025 · Jordi Rodon Ahnert, Sameek Roychowdhury, et al. · Journal of Clinical Oncology · 1

462P TYRA-300: FGFR3 selective and gatekeeper agnostic

2022 · J. Starrett, E. Allen, et al. · Annals of Oncology · 1

100P Co-mutational landscape of key fibroblast growth factor receptor (FGFR) alterations in intra-hepatic cholangiocarcinoma (iCCA), bladder cancer (BC) and glioma

2022 · A. Necchi, K. Murugesan, et al. · Annals of Oncology · 1

FGFR3 Selectivity in Drug Discovery: Biological Rationale, Design Strategies, and Therapeutic Potential

2026 · Jacqueline H. Starrett, Daniel C. Bensen, et al. · Journal of Medicinal Chemistry

A phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib (TYRA-300) in participants with FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302).

2026 · Gautam Jayram, Neal D. Shore, et al. · Journal of Clinical Oncology

SUN-730 TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia

2025 · Jacqueline H Starrett, Clara Lemoine, et al. · Journal of the Endocrine Society

Works count: 17

Citation count: 1,075